The Value of Measuring Inspiratory Capacity in Subjects With Cystic Fibrosis

References

1. 1.↵
   1. Kreda SM,
   2. Davis CW,
   3. Rose MC

   . CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med 2012;2(9):a009589.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Puchelle E,
   2. Bajolet O,
   3. Abély M

   . Airway mucus in cystic fibrosis. Paediatr Respir Rev 2002;3(2):115–119.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Horsley A,
   2. Siddiqui S

   . Putting lung function and physiology into perspective: cystic fibrosis in adults. Respirology 2015;20(1):33–45.

   OpenUrlPubMed
4. 4.↵
   1. Kerem E,
   2. Viviani L,
   3. Zolin A,
   4. MacNeill S,
   5. Hatziagorou E,
   6. Ellemunter H,
   7. et al

   . ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 2014;43(1):125–33.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Kerem E,
   2. Reisman J,
   3. Corey M,
   4. Canny GJ,
   5. Levison H

   . Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326(18):1187–1191.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Vilozni D,
   2. Lavie M,
   3. Ofek M,
   4. Sarouk I,
   5. Bar-Aluma BE,
   6. Dagan A,
   7. et al

   . Consequences of expiratory flow limitation at rest in subjects with cystic fibrosis. Ann Am Thorac Soc 2016;13(6):825–832.

   OpenUrl
7. 7.↵
   1. Casanova C,
   2. Cote C,
   3. de Torres JP,
   4. Aguirre-Jaime A,
   5. Marin JM,
   6. Pinto-Plata V,
   7. Celli BR

   . Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(6):591–597.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.
   1. Tantucci C,
   2. Duguet A,
   3. Similowski T,
   4. Zelter M,
   5. Derenne JP,
   6. Milic-Emili J

   . Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998;12(4):799–804.

   OpenUrlAbstract
9. 9.
   1. O'Donnell DE

   . Breathlessness in patients with chronic airflow limitation. Mechanisms and management. Chest 1994;106(3):904–912.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Diaz O,
    2. Villafranca C,
    3. Ghezzo H,
    4. Borzone G,
    5. Leiva A,
    6. Milic-Emil J,
    7. Lisboa C

    . Role of inspiratory capacity on exercise tolerance in COPD patients with and without expiratory flow limitation at rest. Eur Respir J 2000;16(2):269–275.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Reddy RM,
    2. Guntupalli KK

    . Review of ventilatory techniques to optimize mechanical ventilation in acute exacerbation of chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 2007;2(4):441–452.

    OpenUrlPubMed
12. 12.↵
    1. Calverley PMA

    . Dynamic hyperinflation: is it worth measuring. Proc Am Thoracic Soc 2006;3(3):239–244.

    OpenUrl
13. 13.↵
    1. Boni E,
    2. Corda L,
    3. Franchini D,
    4. Chiroli P,
    5. Damiani GP,
    6. Pini L,
    7. et al

    . Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002;57(6):528–532.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Vilozni D,
    2. Lavie M,
    3. Ofek M,
    4. Sarouk I,
    5. Efrati O

    . Cough characteristics and FVC maneuver in cystic fibrosis. Respir Care 2014;59(12):1912–1917.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Miller MR,
    2. Hankinson J,
    3. Brusasco V,
    4. Burgos F,
    5. Casaburi R,
    6. Coates A,
    7. et al

    . ATS/ERS Task Force. Standardization of spirometry. Eur Respir J 2005;26(2):319–338.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Quanjer PH,
    2. Stanojevic S,
    3. Cole TJ,
    4. Baur X,
    5. Hall GL,
    6. Culver BH,
    7. et al

    . ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40(6):1324–1343.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Cole TJ,
    2. Stanojevic S,
    3. Stocks J,
    4. Coates AL,
    5. Hankinson JL,
    6. Wade AM

    . Age- and size-related reference ranges: a case study of spirometry through childhood and adulthood. Statist Med 2009;28(5):880–898.

    OpenUrlCrossRef
18. 18.↵
    1. Wanger J,
    2. Clausen JL,
    3. Coates A,
    4. Pedersen OF,
    5. Brusasco V,
    6. Burgos F,
    7. et al

    . Standardization of the measurement of lung volumes. Eur Respir J 2005;26(3):511–522.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Polgar G,
    2. Promadhat V

    . Pulmonary function testing in children: techniques and standards. Philadelphia, W. B. Saunders, 1971.
20. 20.↵
    1. Quanjer PH,
    2. Tammeling GJ,
    3. Cotes JE,
    4. Pedersen OF,
    5. Peslin R,
    6. Yernault JC

    . Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl 16):5–40.

    OpenUrlFREE Full Text
21. 21.↵
    1. Ries AL,
    2. Sosa G,
    3. Prewitt L,
    4. Friedman PJ,
    5. Harwood IR

    . Restricted pulmonary function in cystic fibrosis. Chest 1988;94(3):575–579.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.
    1. Holland AE,
    2. Denehy L,
    3. Wilson JW

    . Does expiratory flow limitation predict chronic dyspnoea in adults with cystic fibrosis? Eur Respir J 2006;28(1):96–101.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Rosenthal M

    . Annual assessment spirometry, plethysmography, and gas transfer in cystic fibrosis: do they predict death or transplantation. Pediatr Pulmonol 2008;43(10):945–952.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Davis SD,
    2. Fordham LA,
    3. Brody AS,
    4. Noah TL,
    5. Retsch-Bogart GZ,
    6. Qaqish BF,
    7. et al

    . Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med 2007;175(9):943–950.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Ratjen F,
    2. Döring G

    . Cystic fibrosis. Lancet 2003;361(9358):681–689.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Diwakar A,
    2. Adam RJ,
    3. Michalski AS,
    4. Tamegnon MM,
    5. Fischer AJ,
    6. Launspach JL,
    7. et al

    . Sonographic evidence of abnormal tracheal cartilage ring structure in cystic fibrosis. Laryngoscope 2015;125(10):2398–2404.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Harris RS,
    2. Hess DR,
    3. Venegas JG

    . An objective analysis of the pressure–volume curve in the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161(2 part 1):432–439.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Brochard L

    . What is a pressure–volume curve? Crit Care 2006;10(4):156.

    OpenUrlPubMed
29. 29.↵
    1. Vilozni D,
    2. Lavie M,
    3. Ofek M,
    4. Sarouk I,
    5. Bar-Aluma BE,
    6. Dagan A,
    7. et al

    . Consequences of expiratory flow limitation at rest in subjects with cystic fibrosis. Ann Am Thorac Soc 2016;13(6):825–832.

    OpenUrl
30. 30.↵
    1. O'Donnell DE

    . Ventilatory limitations in chronic obstructive pulmonary disease. Med Sci Sports Exerc 2001;33(Suppl 7):S647–S655.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Hirche TO,
    2. Knoop C,
    3. Hebestreit H,
    4. Shimmin D,
    5. Solé A,
    6. Elborn JS,
    7. et al

    . Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014;2014:621342.

    OpenUrlPubMed